Drugging the HDAC6-HSP90 interplay in malignant cells

Trends in Pharmacological Sciences

Volumn 35, Issue 10, 2014, Pages 501-509

  Krämer, Oliver H ^a   Mahboobi, Siavosh ^b   Sellmer, Andreas ^b  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Acetylation cancer; HDAC6; HDAC6 inhibitor; HSP90 leukemia

Indexed keywords

BCR ABL PROTEIN; BETA CATENIN; CASEIN KINASE I; CASEIN KINASE II; CD133 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; ENTINOSTAT; G PROTEIN COUPLED RECEPTOR KINASE 2; GLYCOGEN SYNTHASE KINASE 3BETA; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; PANOBINOSTAT; RICOLINOSTAT; TRANSCRIPTION FACTOR FOXP3; VALPROIC ACID; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE;

APOPTOSIS; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE ARREST; CELL PROLIFERATION; CELL VIABILITY; DEACETYLATION; DNA DAMAGE; DRUG SELECTIVITY; HUMAN; LEUKEMIA CELL; LEUKEMOGENESIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; PROTEIN ACETYLATION; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN HOMEOSTASIS; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS INHIBITION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; ENZYMOLOGY; METABOLISM; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84907886869     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2014.08.001     Document Type: Review

References (67)

1. E. Seto, and M. Yoshida Erasers of histone acetylation: the histone deacetylase enzymes Cold Spring Harb. Perspect. Biol. 6 2014 a018713
2. U.H. Beier Histone/protein deacetylases control Foxp3 expression and the heat shock response of T-regulatory cells Curr. Opin. Immunol. 23 2011 670
3. S. Müller, and O.H. Krämer Inhibitors of HDACs - effective drugs against cancer? Curr. Cancer Drug Targets 10 2010 210
4. B. Mair Exploiting epigenetic vulnerabilities for cancer therapeutics Trends Pharmacol. Sci. 35 2014 136
5. O.H. Krämer HDAC2: a critical factor in health and disease Trends Pharmacol. Sci. 30 2009 647
6. Y. Li Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes FEBS J. 280 2013 775
7. S. Dallavalle Development and therapeutic impact of HDAC6-selective inhibitors Biochem. Pharmacol. 84 2012 756
8. Y. Liu Modulation of histone deacetylase 6 (HDAC6) nuclear import and tubulin deacetylase activity through acetylation J. Biol. Chem. 287 2012 29168
9. X. Xu Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells PLoS ONE 6 2011 0017138
10. G.I. Aldana-Masangkay, and K.M. Sakamoto The role of HDAC6 in cancer J. Biomed. Biotechnol. 2011 2011 875824
11. K.P. Liu LC3B-II deacetylation by histone deacetylase 6 is involved in serum-starvation-induced autophagic degradation Biochem. Biophys. Res. Commun. 441 2013 970
12. H. Reikvam Heat shock protein 90 - a potential target in the treatment of human acute myelogenous leukemia Curr. Cancer Drug Targets 9 2009 761
13. J. Asthana Inhibition of HDAC6 deacetylase activity increases its binding with microtubules and suppresses microtubule dynamic instability in MCF-7 cells J. Biol. Chem. 288 2013 22516
14. K.V. Butler Rational design and simple chemistry yield a superior neuroprotective HDAC6 inhibitor, tubastatin A J. Am. Chem. Soc. 132 2010 10842
15. M. Nieborowska-Skorska Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors Blood 119 2012 4253
16. R. Godfrey Cell transformation by FLT3 ITD in acute myeloid leukemia involves oxidative inactivation of the tumor suppressor protein-tyrosine phosphatase DEP-1/PTPRJ Blood 119 2012 4499
17. C. Kosan STAT5 acetylation: Mechanisms and consequences for immunological control and leukemogenesis JAKSTAT 2 2013 e26102
18. V. Kapuria A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination Cell. Signal. 23 2011 2076
19. Y. Wang Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells Blood 114 2009 5024
20. O.H. Krämer SIAH proteins: critical roles in leukemogenesis Leukemia 27 2012 792
21. C.A. Bradbury Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors Leukemia 19 2005 1751
22. M. Van Damme HDAC isoenzyme expression is deregulated in chronic lymphocytic leukemia B-cells and has a complex prognostic significance Epigenetics 7 2012 1403
23. L. Marquard Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma Histopathology 53 2008 267
24. V. Patil 3-Hydroxypyridin-2-thione as novel zinc binding group for selective histone deacetylase inhibition J. Med. Chem. 56 2013 3492
25. F.F. Wagner Potent and selective inhibition of histone deacetylase 6 (HDAC6) does not require a surface-binding motif J. Med. Chem. 56 2013 1772
26. E.S. Inks A novel class of small molecule inhibitors of HDAC6 ACS Chem. Biol. 7 2012 331
27. J.A. Bergman Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth J. Med. Chem. 55 2012 9891
28. M. Kaliszczak A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth Br. J. Cancer 108 2013 342
29. J.H. Lee Development of a histone deacetylase 6 inhibitor and its biological effects Proc. Natl. Acad. Sci. U.S.A. 110 2013 15704
30. B. Hackanson HDAC6 as a target for antileukemic drugs in acute myeloid leukemia Leuk. Res. 36 2012 1055
31. L. Santo Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma Blood 119 2012 2579
32. S. Valente tert-Butylcarbamate-containing histone deacetylase inhibitors: apoptosis induction, cytodifferentiation, and antiproliferative activities in cancer cells ChemMedChem 8 2013 800
33. A.V. Schofield Tubulin polymerization promoting protein 1 (Tppp1) phosphorylation by Rho-associated coiled-coil kinase (rock) and cyclin-dependent kinase 1 (Cdk1) inhibits microtubule dynamics to increase cell proliferation J. Biol. Chem. 288 2013 7907
34. M. Mollapour, and L. Neckers Post-translational modifications of Hsp90 and their contributions to chaperone regulation Biochim. Biophys. Acta 3 2012 648
35. K.B. Kaplan, and R. Li A prescription for 'stress' - the role of Hsp90 in genome stability and cellular adaptation Trends Cell Biol. 22 2012 576
36. K.A. Williams Extracellular signal-regulated kinase (ERK) phosphorylates histone deacetylase 6 (HDAC6) at serine 1035 to stimulate cell migration J. Biol. Chem. 288 2013 33156
37. R. Rao HDAC6 inhibition enhances 17-AAG-mediated abrogation of hsp90 chaperone function in human leukemia cells Blood 112 2008 1886
38. A. Mandawat Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists Blood 116 2010 5306
39. J.E. Bradner Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease Proc. Natl. Acad. Sci. U.S.A. 107 2010 12617
40. J. Zhu PKC alpha regulates Sendai virus-mediated interferon induction through HDAC6 and beta-catenin EMBO J. 30 2011 4838
41. A.B. Mak Regulation of CD133 by HDAC6 promotes beta-catenin signaling to suppress cancer cell differentiation Cell Rep. 2 2012 951
42. F.M. Tolba Expression of CD133 in acute leukemia Med. Oncol. 30 2013 013
43. S. Chen HDAC6 regulates mitochondrial transport in hippocampal neurons PLoS ONE 5 2010 0010848
44. R. Kurashina Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells Cancer Lett. 284 2009 62
45. A.V. Schofield Tubulin polymerization promoting protein 1 (TPPP1) increases beta-catenin expression through inhibition of HDAC6 activity in U2OS osteosarcoma cells Biochem. Biophys. Res. Commun. 436 2013 571
46. M. Watabe, and T. Nakaki Protein kinase CK2 regulates the formation and clearance of aggresomes in response to stress J. Cell Sci. 124 2011 1519
47. P. Muller C-terminal phosphorylation of Hsp70 and Hsp90 regulates alternate binding to co-chaperones CHIP and HOP to determine cellular protein folding/degradation balances Oncogene 32 2013 3101
48. F. Piazza Novel players in multiple myeloma pathogenesis: role of protein kinases CK2 and GSK3 Leuk. Res. 37 2013 221
49. Y. Han Acetylation of histone deacetylase 6 by p300 attenuates its deacetylase activity Biochem. Biophys. Res. Commun. 383 2009 88
50. C. Nishioka MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells Leuk. Res. 32 2008 1382
51. T-Y. Lin AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit Blood 115 2010 4217
52. Y. Yang Role of acetylation and extracellular location of heat shock protein 90α in tumor cell invasion Cancer Res. 68 2008 4833
53. A. Newbold Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities Mol. Cancer Ther. 12 2013 2709
54. Y. Wang FK228 inhibits Hsp90 chaperone function in K562 cells via hyperacetylation of Hsp70 Biochem. Biophys. Res. Commun. 356 2007 998
55. W. Fiskus Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells Blood 112 2008 2896
56. C. Choudhary Lysine acetylation targets protein complexes and co-regulates major cellular functions Science 325 2009 834
57. B.T. Scroggins An acetylation site in the middle domain of Hsp90 regulates chaperone function Mol. Cell 25 2007 151
58. V. Lafarga A novel GRK2/HDAC6 interaction modulates cell spreading and motility EMBO J. 31 2012 856
59. S. Legros The HTLV-1 Tax protein inhibits formation of stress granules by interacting with histone deacetylase 6 Oncogene 30 2011 4050
60. L. Gao, and E.W. Harhaj HSP90 protects the human T-cell leukemia virus type 1 (HTLV-1) tax oncoprotein from proteasomal degradation to support NF-kappaB activation and HTLV-1 replication J. Virol. 87 2013 13640
61. M.J. Chuang The HDAC inhibitor LBH589 induces ERK-dependent prometaphase arrest in prostate cancer via HDAC6 inactivation and down-regulation PLoS ONE 8 2013 e73401
62. K.C. Chan A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation Mol. Cancer 12 2013 1476
63. R. Baruchello 4,5,6,7-Tetrahydro-isoxazolo-[4,5-c]-pyridines as a new class of cytotoxic Hsp90 inhibitors Eur. J. Med. Chem. 76 2014 53
64. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646
65. S. Schaefer Phenylalanine-containing hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs) Bioorg. Med. Chem. 16 2008 2011
66. J.H. Kalin Second-generation histone deacetylase 6 inhibitors enhance the immunosuppressive effects of Foxp3+ T-regulatory cells J. Med. Chem. 55 2012 639
67. V.R. De Potent and selective HDAC6 inhibitory activity of N-(4-hydroxycarbamoylbenzyl)-1,2,4,9-tetrahydro-3-thia-9-azafluorenes as novel sulfur analogues of tubastatin A Chem. Commun. (Camb) 49 2013 3775